Company intelligence / Profile preview

Iterion Therapeutics

Houston, Texas, United Statesiteriontherapeutics.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Iterion Therapeutics has completed a Phase 1 trial establishing safety and clinical activity of its lead candidate tegavivint. The company has initiated or announced multiple clinical trials including a Phase 1b/2a study in advanced hepatocellular carcinoma, as well as studies in large B-cell lymphoma and desmoid tumors. Tegavivint shows promise by targeting the Wnt/beta-catenin pathway through TBL1 inhibition—a novel approach for cancers with high unmet need.[1]

Therapeutic areas: Oncology
Modalities: Small molecules[1][2]
Industry: Biotech

Drug pipeline

1 asset

tegavivint

Partnerships

Collaborations with leading academic institutions for investigator-sponsored trials; specific partners not named but described as deep collaborative relationships[1]

Beyond the preview

Go deeper on Iterion Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Iterion Therapeutics.